Pharmacy bulletin 1ed 2015
... A) Non-opioid analgesic Non-opioid analgesics are the most common pain-killers prescribed. The common ones are paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs). Paracetamol ...
... A) Non-opioid analgesic Non-opioid analgesics are the most common pain-killers prescribed. The common ones are paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs). Paracetamol ...
Thank OD - Panacea Biotec
... administration of drug upto 5gm/kg dose. The sub-acute toxicity studies were conducted in rats and guinea pigs by using their 1/5,1/ 10 and 1/20 of LD-50 doses achieved by i.p. route. The drug was administered p.o. daily for 14 days. The test groups of animals did not show any signs of toxicity and ...
... administration of drug upto 5gm/kg dose. The sub-acute toxicity studies were conducted in rats and guinea pigs by using their 1/5,1/ 10 and 1/20 of LD-50 doses achieved by i.p. route. The drug was administered p.o. daily for 14 days. The test groups of animals did not show any signs of toxicity and ...
QA53_7_Hypersalivationalternatives
... weeks with a 1-week washout before crossover. The initial benzatropine dose was 500 microgram to 2mg daily, depending on the patient’s age and weight, as a single daily dose. This was increased at 1-2 day intervals until no or infrequent drooling occurred, to a maximum dose of 6mg daily. The dose wa ...
... weeks with a 1-week washout before crossover. The initial benzatropine dose was 500 microgram to 2mg daily, depending on the patient’s age and weight, as a single daily dose. This was increased at 1-2 day intervals until no or infrequent drooling occurred, to a maximum dose of 6mg daily. The dose wa ...
Hormone Therapy for Treatment of Menopausal
... in late-stage post menopause, and findings may not generalize to younger, early perimenopausal and early postmenopausal women. A notable criticism of the WHI studies is that findings based on a sample of primarily older, late postmenopausal women have been inappropriately generalized to younger, ear ...
... in late-stage post menopause, and findings may not generalize to younger, early perimenopausal and early postmenopausal women. A notable criticism of the WHI studies is that findings based on a sample of primarily older, late postmenopausal women have been inappropriately generalized to younger, ear ...
Name Change – OMACOR to LOVAZA
... OMACOR is indicated as an adjunct to diet to reduce very high (≥500 mg/dL) triglyceride (TG) levels in adult patients. Diseases contributory to hyperlipidemia (such as hypothyroidism or diabetes mellitus) should be looked for and adequately treated. Certain drugs (estrogen, thiazide diuretics and be ...
... OMACOR is indicated as an adjunct to diet to reduce very high (≥500 mg/dL) triglyceride (TG) levels in adult patients. Diseases contributory to hyperlipidemia (such as hypothyroidism or diabetes mellitus) should be looked for and adequately treated. Certain drugs (estrogen, thiazide diuretics and be ...
Document
... controlled release capsules. Adults with OCD are often started at a dose of 50 mg administered at bedtime. The dose may be increased by 50 mg every 4 to 7 days. The effective dosing range in premarketing trials with OCD was 100 to 300 mg per day, although, clearly, some patients do respond to higher ...
... controlled release capsules. Adults with OCD are often started at a dose of 50 mg administered at bedtime. The dose may be increased by 50 mg every 4 to 7 days. The effective dosing range in premarketing trials with OCD was 100 to 300 mg per day, although, clearly, some patients do respond to higher ...
Nonsteroidal Anti-inflammatory Drugs, Disease
... • A nonselective COX inhibitor • Also inhibits PMN leukocyte migration, decreases O2 radical production, & inhibits lymphocyte function • Mean t1/2: 50-60 hrs • Dosing: o.d. or every other day ...
... • A nonselective COX inhibitor • Also inhibits PMN leukocyte migration, decreases O2 radical production, & inhibits lymphocyte function • Mean t1/2: 50-60 hrs • Dosing: o.d. or every other day ...
maxair™ autohaler
... times the maximum recommended daily inhalation dose for adults and children on a mg/m2 basis) showed no evidence of carcinogenicity. In an 18-month study in mice at dietary doses of 1.0, 3.0, and 10 mg/kg (approximately 2, 5, and 15 times the maximum recommended daily inhalation dose for adults and ...
... times the maximum recommended daily inhalation dose for adults and children on a mg/m2 basis) showed no evidence of carcinogenicity. In an 18-month study in mice at dietary doses of 1.0, 3.0, and 10 mg/kg (approximately 2, 5, and 15 times the maximum recommended daily inhalation dose for adults and ...
Full Prescribing Information
... There are no adequate and well-controlled studies of ERWINAZE in pregnant women. In embryofetal development studies in rats and rabbits, asparaginase Erwinia chrysanthemi produced embryofetal toxicities and fetal abnormalities. ERWINAZE should be used during pregnancy only if the potential benefit j ...
... There are no adequate and well-controlled studies of ERWINAZE in pregnant women. In embryofetal development studies in rats and rabbits, asparaginase Erwinia chrysanthemi produced embryofetal toxicities and fetal abnormalities. ERWINAZE should be used during pregnancy only if the potential benefit j ...
Back_to_basics_pharmacology 1, 2 and 3 2011
... – all opioids have the potential to cause skin itchiness which is not considered an allergic reaction – in all cases, monitor patient for possible cross-allergic reactions ...
... – all opioids have the potential to cause skin itchiness which is not considered an allergic reaction – in all cases, monitor patient for possible cross-allergic reactions ...
Pharmacy Updates in Cardiology
... Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs sub ...
... Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs sub ...
![Mefenamic Acid tablets 500 mg BP [dtw]](http://s1.studyres.com/store/data/008012106_1-d03734e057378a8035fde5725d328ab3-300x300.png)
Mefenamic Acid tablets 500 mg BP [dtw]
... In dysmenorrhoea it should be administered at the onset of menstrual pain and continued according to the judgement of the physician. Children It is recommended that children under 12 years of age should be given mefenamic acid Suspension (50mg/5ml). The Elderly (over 65 years) As for adults. Whilst ...
... In dysmenorrhoea it should be administered at the onset of menstrual pain and continued according to the judgement of the physician. Children It is recommended that children under 12 years of age should be given mefenamic acid Suspension (50mg/5ml). The Elderly (over 65 years) As for adults. Whilst ...
Halocort
... Apply a thin layer of Halocort® to the affected skin once or twice daily, as directed by the physician, and rub in gently and completely. Halocort® is a super-high potency topical corticosteroid; therefore, treatment beyond two consecutive weeks is not recommended, and the total dosage should not ex ...
... Apply a thin layer of Halocort® to the affected skin once or twice daily, as directed by the physician, and rub in gently and completely. Halocort® is a super-high potency topical corticosteroid; therefore, treatment beyond two consecutive weeks is not recommended, and the total dosage should not ex ...
SYNACTHEN DEPOT im
... There is a limited amount of data on the use of Synacthen in pregnant patients. Data from animal studies are insufficient with respect to reproductive toxicity/teratogenicity. Synacthen should be used during pregnancy only if the expected benefit outweighs the potential risk to the foetus. Breast-fe ...
... There is a limited amount of data on the use of Synacthen in pregnant patients. Data from animal studies are insufficient with respect to reproductive toxicity/teratogenicity. Synacthen should be used during pregnancy only if the expected benefit outweighs the potential risk to the foetus. Breast-fe ...
Myonal Myonal
... Blood concentration Eperisone hydrochloride was administered orally to 8 healthy adult male volunteers at a single dose of 150 mg once daily note) for 14 consecutive days and the plasma concentration was determined on days 1, 8 and 14. The time to reach the peak plasma concentration (tmax) ranged fr ...
... Blood concentration Eperisone hydrochloride was administered orally to 8 healthy adult male volunteers at a single dose of 150 mg once daily note) for 14 consecutive days and the plasma concentration was determined on days 1, 8 and 14. The time to reach the peak plasma concentration (tmax) ranged fr ...
DESIGNING OF POTENTIAL NEW ESTROGEN ANTAGONISTS FOR TREATMENT OF
... inhibitors both are generally used to treat endometriosis. But the large side effect profile of aromatase inhibitor are like Osteoporosis, increased coronary heart disease, and more over cost of treatment is more as compared with the treatment of estrogen antagonist. Due to many other factors these ...
... inhibitors both are generally used to treat endometriosis. But the large side effect profile of aromatase inhibitor are like Osteoporosis, increased coronary heart disease, and more over cost of treatment is more as compared with the treatment of estrogen antagonist. Due to many other factors these ...
Injectable Fertility Medications
... o For coverage of GnRH antagonists, GnRH agonists, progestins, or gonadotropins, at least ONE of the following conditions is met: Documented severe (Stage 4) endometriosis is confirmed OR Documented diminished ovarian function (DOR) such as elevation in 3-day FSH level (above 10-14 mIU/ml) is confir ...
... o For coverage of GnRH antagonists, GnRH agonists, progestins, or gonadotropins, at least ONE of the following conditions is met: Documented severe (Stage 4) endometriosis is confirmed OR Documented diminished ovarian function (DOR) such as elevation in 3-day FSH level (above 10-14 mIU/ml) is confir ...
06_Multiple dosing Extravascular Administration
... QJ is a 67-year-old, 80-kg male being treated for chronic obstructive pulmonary disease. Sustained-release oral theophylline is being added to his drug regimen. Assuming F = 1.0, V = 40 L, and t1/2 = 5 hours, compute an oral theophylline dose to be administered every 12 hours that would achieve a Cs ...
... QJ is a 67-year-old, 80-kg male being treated for chronic obstructive pulmonary disease. Sustained-release oral theophylline is being added to his drug regimen. Assuming F = 1.0, V = 40 L, and t1/2 = 5 hours, compute an oral theophylline dose to be administered every 12 hours that would achieve a Cs ...
Stelazine® Presentations Indications Dosage and Administration
... pseudo-parkinsonism and dystonias are all recognised as extrapyramidal in origin, and may occur during the administration of these compounds. The incidence of such side effects varies widely, but is lowest when the drug is increased gradually to an optimal therapeutic level. Depending on the severit ...
... pseudo-parkinsonism and dystonias are all recognised as extrapyramidal in origin, and may occur during the administration of these compounds. The incidence of such side effects varies widely, but is lowest when the drug is increased gradually to an optimal therapeutic level. Depending on the severit ...
Otomax Label - MSD Animal Health New Zealand
... administered orally or parenterally to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, foetal death, retained placenta and metritis. Administration of recommended doses of OTOMAX beyond 7 ...
... administered orally or parenterally to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, foetal death, retained placenta and metritis. Administration of recommended doses of OTOMAX beyond 7 ...
The oral delivery of macromolecules
... by creating a more user-friendly dosage form. This would have the advantage of increasing the use of prescribed medications, thereby reducing the incidence of disease. Since oral dosage forms can be taken on an outpatient basis, the burden on clinics and hospitals to administer such drugs would be r ...
... by creating a more user-friendly dosage form. This would have the advantage of increasing the use of prescribed medications, thereby reducing the incidence of disease. Since oral dosage forms can be taken on an outpatient basis, the burden on clinics and hospitals to administer such drugs would be r ...
Palliative Care Symptom Guide
... 4.The hour limit should not be less than the available total hourly patient doses (delivered through the infuser) that are titrated to achieve an adequate administered dose. Bolus doses and the continuous infusion are included level of analgesia (pain score less than or equal to 4/10). in the one-ho ...
... 4.The hour limit should not be less than the available total hourly patient doses (delivered through the infuser) that are titrated to achieve an adequate administered dose. Bolus doses and the continuous infusion are included level of analgesia (pain score less than or equal to 4/10). in the one-ho ...
Prazole Capsule - Renata Limited
... the stimulus. After oral administration, the onset of the antisecretory effect of Omeprazole (Prazole®) occurs within one hour, with the maximum effect occurring within two hours. Inhibition of recreation is about 50% of maximum at 24 hours and the duration of inhibition lasts upto 72 hours. Omepraz ...
... the stimulus. After oral administration, the onset of the antisecretory effect of Omeprazole (Prazole®) occurs within one hour, with the maximum effect occurring within two hours. Inhibition of recreation is about 50% of maximum at 24 hours and the duration of inhibition lasts upto 72 hours. Omepraz ...
Swine: Baytril® 100 is indicated for the treatment and control of
... Cattle: A total of 845 calves with naturally-occurring BRD were treated with Baytril® 100 in eight field trials located in five cattlefeeding states. Response to treatment was compared to non-treated controls. Single-dose and multiple-day therapy regimens were evaluated. BRD and mortality were signi ...
... Cattle: A total of 845 calves with naturally-occurring BRD were treated with Baytril® 100 in eight field trials located in five cattlefeeding states. Response to treatment was compared to non-treated controls. Single-dose and multiple-day therapy regimens were evaluated. BRD and mortality were signi ...
Treatment for uterine fibroids: Searching for effective drug therapies
... tamoxifen, significantly reducing fibroid size in postmenopausal women yet is less efficacious at reducing tumor volume in premenopausal women [18]. Clinical outcomes in premenopausal women treated with raloxifene suggest that this compound, like tamoxifen, can affect the ovaries via the HPO axis. T ...
... tamoxifen, significantly reducing fibroid size in postmenopausal women yet is less efficacious at reducing tumor volume in premenopausal women [18]. Clinical outcomes in premenopausal women treated with raloxifene suggest that this compound, like tamoxifen, can affect the ovaries via the HPO axis. T ...
Dydrogesterone
Dydrogesterone (INN, USAN, BAN), is also chemically known as 9β,10α-pregna-4,6-diene-3,20-dione. Dydrogesterone (6-dehydro-retroprogesterone) is a hormonally active, non-androgenic steroid that was developed in the 1950s.Dydrogesterone has selective progestational activity and does not inhibit ovulation. The greater rigidity of dydrogesterone also positively affects its selectivity, while natural progesterone is less selective, existing in different conformations that more easily bind to different receptors. As a consequence of its better bioavailability and the progestational activity of its main metabolites (20-, 21- and 16-hydroxy derivatives), the equivalent dose of dydrogesterone is 10–20 times lower than that of oral micronized progesterone.Dydrogesterone is used as an effective, orally active progestogen for gynaecological conditions related to a wide variety of progesterone deficiencies in pregnant women. The molecular structure and pharmacological effects are somewhat similar to endogenous progesterone, although in smaller amounts it is found to be orally active. Its freedom from hormonal effects like those related to corticoid, androgenic, estrogenic, anabolic, and other effects gives dydrogesterone an advantage over other synthesized progestogens.Dydrogesterone when used therapeutically is closely related to its physiological action on the neuro-endocrine control of ovarian function, as well as on the endometrium. This is an indication in all cases of endogeneous progesterone deficiency - relative or absolute. The molecule was licensed for use in several indications, including threatened or recurrent miscarriage, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhoea, irregular cycles, pre-menstrual syndrome and also as a hormone replacement therapy.Dydrogesterone has proven effective in the following conditions associated with progesterone deficiency: Infertility due to luteal insufficiency Threatened miscarriage Habitual or recurrent miscarriage. Menstrual disorders Premenstrual syndrome Endometriosis Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counter-check the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone acetate.